Barbara Burtness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate PEPINEMAB IN COMBINATION WITH PEMBROLIZUMAB for first-linetreatment...

Title: “Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer” Presented by: Barbara Burtness, MD Professor of Medicine, Department of Medical Oncology Yale School of Medicine Location: New Research Building Auditorium with Zoom option Lecture Series Presented by Georgetown Lombardi Comprehensive Cancer Center  About the Speaker: Barbara Burtness, MD, is professor of medicine (Medical Oncology) […]

Sarah Goldberg, MD, MPH, highlights the mechanism of action of VIC-1911, expands on its ongoing investigation in the phase 1 trial, and sheds light on next steps planned for the agent’s investigation in KRAS G12C–mutant non–small cell lung cancer.

The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.The benefit appeared confined to individuals with HPV-negative disease, and a phase 3 trial to further evaluate the regimen in that population is planned.

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.